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AbstrAct
Clear cell renal cell carcinomas (ccRCCs) harbor frequent mutations in epigenetic 
modifiers including SETD2, the H3K36me3 writer. We profiled DNA methylation (5mC) 
across the genome in cell line-based models of SETD2 inactivation and SETD2 mutant 
primary tumors because 5mC has been linked to H3K36me3 and is therapeutically 
targetable. SETD2 depleted cell line models (long-term and acute) exhibited a DNA 
hypermethylation phenotype coinciding with ectopic gains in H3K36me3 centered 
across intergenic regions adjacent to low expressing genes, which became upregulated 
upon dysregulation of the epigenome. Poised enhancers of developmental genes were 
prominent hypermethylation targets. SETD2 mutant primary ccRCCs, papillary renal 
cell carcinomas, and lung adenocarcinomas all demonstrated a DNA hypermethylation 
phenotype that segregated tumors by SETD2 genotype and advanced grade. These 
findings collectively demonstrate that SETD2 mutations drive tumorigenesis by 
coordinated disruption of the epigenome and transcriptome,and they have important 
implications for future therapeutic strategies targeting chromatin regulator mutant 
tumors.
IntroductIon
Cancer of the kidney and renal pelvis affects > 
65,000 patients annually and ranks 8th in causes of cancer 
death in the United States. The most common histologic 
subtype is clear cell renal cell cancer (ccRCC), which 
accounts for the majority of RCC-related deaths. Surgery 
remains the standard of care for patients with early stage 
tumors, however ~30% of patients progress to distant 
metastases after surgery for localized disease. Despite 
some advances in systemic therapy, median survival drops 
to about two years after development of metastatic disease 
[1]. CcRCC differs from many tumor types in that it is 
characterized by frequent mutation of epigenetic regulators 
(dominated by SETD2 (10-15%), PBRM1 (33-45%), and 
BAP1 (15%)), while mutations in other common cancer 
gene pathways (e.g. RAS, BRAF, TP53, RB) are largely 
absent [2-5], and ccRCC is tightly linked to a distinct 
transcriptional signature due to inactivation of the VHL 
gene, which is mediated in part through deregulation of 
the epigenome [6]. These properties also make ccRCC an 
ideal tumor type to use as a model for determining how 
mutations in epigenetic regulator genes modulate tumor 
initiation and progression.
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SETD2 is a ubiquitiously expressed SET domain-
containing histone 3 lysine 36 trimethylase (H3K36me3) 
that interacts with elongating RNA pol II via the RNA 
pol II-associated factor complex (PAF1c), to recruit 
H3K36me3 to transcribing gene bodies [7-10]. SETD2 is 
the principle mediator of H3K36me3 and has little if any 
role in generating H3K36me1/me2 [11-13]. Functions for 
H3K36me3 include regulation of Pol II and nucleosome 
density across exons [2, 14], alternative splicing [15], 
and DNA repair [16, 17]. In ccRCC, biallelic SETD2 
inactivation is associated with reduced survival and earlier 
time to recurrence [18, 19]. Metastatic ccRCC displays 
markedly reduced H3K36me3 levels compared to matched 
primary ccRCCs [13]. These findings strongly suggest 
that SETD2 mutations drive tumor progression, yet the 
underlying mechanism remains unknown.
Like H3K36me3, DNA methylation (5mC) is 
enriched across gene bodies [20] where it is positively 
linked to transcription [21] and regulates intragenic 
enhancer activity [22]. Four DNA methyltransferase family 
members, DNMT1, 3A, 3B, and 3L collectively establish 
and maintain genome-wide patterns of DNA methylation 
[23]. 5mC patterns in cancer are profoundly disrupted, 
with global hypomethylation affecting repetitive DNA and 
gene bodies accompanied by more focused promoter/CpG 
island (CGI)/CGI shore hypermethylation that silences the 
associated gene. Aberrant DNA methylation is sufficient 
to drive tumorigenesis in the absence of genetic mutations 
[24]. A direct link between DNA and H3K36 methylation 
was first revealed through in vitro binding studies, 
wherein recombinant Dnmt3a bound H3K36me2/me3-
containing peptides and nucleosomes via its N-terminal 
PWWP domain [25] and subsequent chromatin interaction 
assays showed that H3K36me3 co-immunoprecipitates 
with Dnmt3b [26]. The PWWP domain is a moderately 
conserved motif in > 60 proteins, many of which associate 
with chromatin [27], that is now recognized as a reader 
domain for H3K36 methylation [15, 28]. 
The collective findings linking 5mC to H3K36me3 
and SETD2 mutations to ccRCC motivated us to 
examine their interplay in SETD2 mutant tumors. Using 
cell line models we show that SETD2 loss-of-function 
induces global loss of H3K36me3, but also formation 
of ectopic H3K36me3. SETD2 inactivation also results 
in global redistribution of 5mC, with a predominance 
of hypermethylation events targeted to sites of ectopic 
H3K36me3, intergenic loci, and normal kidney poised 
enhancers. Functionally, global DNA hypermethylation 
events occur in large DMRs conserved across multiple 
tumor types with SETD2 mutations and result in up-
regulation of lowly expressed genes that collectively 
appear to drive cells toward a more undifferentiated state.
results
Validation of SETD2 knockout (Ko) 786-o cells 
as a model of SETD2 mutated ccrcc
To generate a model to study the impact of SETD2 
mutations, we utilized the 786-O ccRCC cell line and 
targeted the SETD2 locus for inactivation using zinc-finger 
nucleases (ZFNs). Two independent clones were isolated 
and characterized. In KO1 the ZFN-nuclease generated a 
4 bp deletion and in KO2 an 11 bp deletion in SETD2, 
both causing frameshifts (Figure S1A). The two SETD2 
isogenic KO clones derived from parental 786-O ccRCC 
cells were validated by Sanger sequencing and cell line 
authentication (ATCC, data available upon request). 
Altered epigenetic phenotypes were highly consistent 
between the SETD2 KO1 and KO2 clones, as will be 
described. 
Since one of our goals was to determine the 
impact of SETD2 loss-of function on 5mC patterns, 
we first examined the impact of this mutation on 
components of the DNA methylation machinery by 
RNA-seq and qRT-PCR (Figure S1B). In 786-O parental 
cells, DNMT1 was the most highly expressed DNMT 
(Figure S1B, left axis) consistent with its role as the 
maintenance methyltransferase. Expression of the de 
novo methyltransferases was low in parental 786-O 
cells; DNMT3L was undetectable (Figure S1B, left 
axis). Inactivation of SETD2 in 786-O cells down-
regulated DNMT1 and up-regulated DNMT3B to 
some extent; DNMT3A and DNMT3L expression did 
not change (Figure S1B, right axis). Expression of the 
TETs in parental 786-O was variable (Figure S1B, left 
axis). SETD2 inactivation resulted in down-regulation 
of TET1 and up-regulation of TET3 (Figure S1B, right 
axis). Taken together, there were no consistent changes in 
expression of DNA methylation machinery components 
that would likely account for global changes in 5mC 
between parental and SETD2 KO 786-O clones. Since the 
DNMTs and TETs play important roles in development, 
we also assayed expression of pluripotency and germ 
layer markers upon SETD2 inactivation (Figure S1C). 
SETD2 KO altered expression of these markers with up-
regulation of pluripotency markers and variable changes 
in expression among germ layer markers (Figure S1C). 
Subunits of the PAF complex, which interacts with both 
SETD2 and the DNMT3s [8, 29] remained constant 
(Figure S1C). 
loss of setd2 induces redistribution of 
H3K36me3
SETD2 KO in 786-O cells resulted in global 
reduction of H3K36me3 with little effect on total 
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H3K36me1 and H3K36me2 (Figure 1A). However, 
H3K36me3 was not completely depleted upon 
SETD2 inactivation using moderate exposures in 
the western blotting. We next performed chromatin 
immunoprecipitation sequencing (ChIP-seq) of 
H3K36me3 in 786-O parental and SETD2 KO clones 
to map its genome-wide distribution. Consistent with 
reduction of H3K36me3 upon SETD2 inactivation (Figure 
1A), coverage from H3K36me3 ChIP-seq (relative to the 
total bp covered by sequence reads) decreased to 17.6% 
and 15.2% for clone 1 and clone 2, respectively, from 
31.4% observed in parental 786-O cells. As expected, 
the majority of H3K36me3 peaks observed in parental 
786-O cells were enriched within gene bodies (Figure 
1B). In the SETD2 KO clones, however, a marked 
redistribution of the remaining H3K36me3 was observed, 
with gains of this mark primarily occurring in intergenic 
regions (Figure 1B). Loss of H3K36me3 also occurred 
Figure 1: reduction and redistribution of H3K36me3 upon inactivation of SETD2 in 786-o ccrcc cells. A. Western blot 
of H3K36 methylation in parental 786-O cells and two independent SETD2 KO clones. Histone H3 is a loading control. b. Distribution of 
H3K36me3 ChIP-seq peaks genome-wide in 786-O ccRCC cells. c. Box plots for H3K36me3 peak length across genomic features. Mean 
line is represented in red. d. Number of genes with ≥ 2-fold-change in H3K36me3 level in SETD2 KO clone 2. e. Representative browser 
shots demonstrating loss and gain of H3K36me3 in SETD2 KO2 clone. Top panel represents intergenic regions that gain H3K36me3. Bent 
arrows = TSS, Green bars = CpG islands. See also Figure S1, S2. 
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upon SETD2 inactivation, as would be expected, with 
nearly 40% fewer H3K36me3 peaks observed in gene 
bodies of the KOs relative to parental 786-O (Figure 
1B). Indeed, the length of peaks across gene bodies was 
reduced among the SETD2 KO clones relative to the 
parental 786-O cells, while the peak length in intergenic 
regions increased with SETD2 inactivation (Figure 1C). 
To evaluate the possibility of non-specific binding of the 
H3K36me3 ChIP antibody, we performed dot blotting 
with peptides containing other histone modifications 
and determined that the antibody had high specificity for 
H3K36me3 and no cross reactivity with H3K36me2 or 
H3K36me1 (Figure S2A). We next assayed differential 
enrichment of H3K36me3 by SICER-DF analysis [30] 
among the 786-O parental and SETD2 KO clones. Loss of 
H3K36me3 in SETD2 KO clones occurred predominately 
in gene bodies (Figure 1D, Figure S2B). However, a small 
number of genes gained H3K36me3 upon inactivation 
of SETD2 with no marked enrichment in any particular 
feature (Figure 1D, Figure S2B). Regions of the genome 
that gained and lost H3K36me3 were highly conserved 
among both independent SETD2 KO clones (Figure 1E, 
Figure S2C). As gains in H3K36me3 were unexpected, 
we validated our H3K36me3 ChIP-seq with locus-
specific ChIP-qPCR (Figure S2D). Overall, we observed 
predominantly reduction in H3K36me3 as a result of 
SETD2 KO in 786-O cells, but also gains of H3K36me3 
over gene bodies and intergenic regions. 
setd2 inactivation results in dnA 
hypermethylation that coincides with regions of 
ectopic H3K36me3
Since H3K36me3 and 5mC overlap significantly 
in their genome-wide distribution [21, 26, 30, 31] we 
next assayed DNA methylation patterns in the 786-O 
isogenic clones using the Illumina HumanMethylation450 
BeadChip (450K array). Globally, DNA hypermethylation 
was observed in both SETD2 KO clones at all genomic 
features, but particularly intergenic regions (Figure 2A-left, 
Figure S3A). Quantification of total genomic 5mC content 
by LC-MS/MS [32] confirmed this observation, revealing 
that SETD2 inactivation resulted in > 20% increase in 
total 5mC in both SETD2 KO clones (Figure 2A-right). 
Analysis of the most differentially methylated CpGs 
(ǀΔβǀ≥0.2) from the 450K array revealed that greater than 
80% of differential methylation upon SETD2 inactivation 
was in the direction of hypermethylation (Figure 2B, 
Figure S3B). DNA hypermethylation was focused 
primarily in intergenic regions while hypomethylation was 
enriched at gene termini where both H3K36me3 and 5mC 
peak under normal conditions (Figure S3C). Independent 
MeDIP-qPCR analysis validated the elevated 5mC events 
identified by 450K array (CTNNA2, AJAP1, and SLIT2) 
(Figure S3D). Additionally, we included in our MeDIP-
qPCR confirmation an intergenic region on chromosome 
5 that was validated for ectopic H3K36me3 (Figure S3D) 
as the 450K array does not provide coverage of this locus. 
Although subtle (most likely due to low CpG density of 
this region), hypermethylation of this intergenic region 
was observed in both SETD2 KO clones (Figure S3D). 
Next, we integrated the genome-wide distribution 
of DNA methylation and H3K36me3 in the isogenic 
786-O cells to determine if they were coordinated. Genes 
that lost H3K36me3 upon SETD2 KO did not display 
alterations in 5mC (Figure 2C, S3E top panel), rather 
DNA hypermethylation occurred at loci that acquired 
ectopic H3K36me3 (bottom panels in Figure 2C, Figure 
S3E). To further investigate the effect that H3K36me3 
distribution had on 5mC, we assigned differentially 
methylated CpGs to categories based on occurrence 
with differential H3K36me3 peaks (Figure 2D, Figure 
S3F). Hypermethylated CpGs significantly overlapped 
with regions that gained H3K36me3 (Figure 2D, Figure 
S3F) with particular enrichment in intergenic regions 
(Figure 2D, Figure S3F, right). Hypomethylated CpGs 
significantly coincided with regions losing H3K36me3 at 
gene termini (Figure 2D, Figure S3F, right). Contrary to 
the observation that loss of H3K36me3 does not influence 
global 5mC distribution, our focused analysis reveals that 
a subset of gene termini do in fact require H3K36me3 for 
proper establishment of 5mC, suggesting that the interplay 
between H3K36me3 and 5mC differs within the gene 
body domain or can be influenced by other processes (e.g. 
3’-end definition versus elongation or splicing).
Poised enhancers in normal adult kidney are 
targeted for dnA hypermethylation and ectopic 
H3K36me3 in ccrcc
H3K4me1 is localized to both poised and active 
enhancers, while H3K27ac marks active enhancers [33]. 
Active enhancers are typically devoid of 5mC as these 
regions are hotspots for transcription factor binding [34]. 
To investigate the epigenetic regulation of enhancers in 
SETD2 mutated ccRCC, we integrated ChIP-seq data 
for H3K4me1 and H3K27ac from normal adult human 
kidney (Epigenome Roadmap) with our 5mC and 
H3K36me3 profiles for 786-O parental and SETD2 KO 
cells. We observed co-occurrence of hypermethylation 
in regions marked exclusively by H3K4me1 genome-
wide, while regions marked with H3K27ac displayed 
hypermethylation in intergenic regions only (Figure 2E). 
Overlap analysis of the most differentially methylated 
CpGs in 786-O SETD2 KOs revealed significant 
enrichment of hypermethylated CpGs at regions marked 
by H3K4me1 in normal adult kidney and exclusion of 
differential methylation at H3K27ac-marked regions 
(Figure S3G). Next, we classified genes from normal 
adult kidney marked with K4me1 only, K4me1+K27ac, or 
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Figure 2: distribution of dnA methylation genome-wide and integration with H3K36me3 under setd2 loss-of-
function conditions. A. Left. Box plots representing all Δβ-values (change in 5mC) in the indicated features. Right. Quantification of 
total 5mC levels in genomic DNA by LC-MS/MS. Each sample was run in duplicate and values are the average and standard deviation 
relative to parental 786-O set at 100%. The 5mC increases in both KO1 and KO2, relative to 786-O are significant (two-sample t test). 
Actual average 5mC/106 dC values are: 786-O 42,083, KO1 52,581, and KO2 57,367. b. Percentage of differentially methylated CpG sites 
(ǀΔβǀ ≥ 0.2) classified by methylation change upon SETD2 KO (hypo/hypermethylation). c. Spatial distribution plots of DNA methylation 
across intragenic regions derived from average β-values stratified by loss or gain in H3K36me3 upon SETD2 KO. d. Left: Scatter plot of 
differentially methylated CpGs (ǀΔβǀ ≥ 0.2) within peaks of H3K36me3 in 786-O cells indicating change in methylation (x-axis) versus 
change in H3K36me3 (y-axis). Number of CpGs is provided in the corner of each quadrant along with significance of 5mC/H3K36me3 
overlap. Green = significant overlap; Red = significant exclusion. Right: Genomic feature enrichment plots normalized to the number of 
CpGs present in each feature on the 450K array for categories with significant overlap. e. Box plots representing the change in methylation 
of CpGs in peaks with the specified enhancer marks stratified by genomic feature. Enhancer mark annotations are derived from normal 
adult human kidney H3K27ac and H3K4me1 ChIP-seq from the Epigenome Roadmap. F. Left: Venn diagram of genes hypermethylated 
upon SETD2 KO and marked exclusively by H3K4me1 in adult human kidney. Right: Biological process ontology of the overlapping gene 
set. See also Figure S3.
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Figure 3: redistribution of H3K36me3 with setd2 inactivation is linked to changes in expression. A. Box plot showing 
the fold-change in H3K36me3 relative to parental 786-O cells at high and low expressing genes based on RPKM values. b. Number of 
genes up-/down-regulated (≥ 2 fold change) in each expression tier (high/low) classified by whether the gene demonstrated loss or gain 
in H3K36me3 upon SETD2 KO. * = overlap (pval < E-50), ‡ = exclusion (pval < E-50) c. Heatmaps demonstrating the average DNA 
methylation level, change in methylation, and overall expression change for genes that lose/gain H3K36me3. 5mC level and the change in 
5mC for CpGs (450K array) in genes that lose (top) or gain (bottom) H3K36me3 were averaged based on genomic location (P = promoter, 
B = body). Each row represents a gene. d. Number of CpGs showing the indicated change in H3K36me3 and 5mC stratified by expression 
tier and change in expression. * = overlap (pval < E-10) e. Browser shots demonstrating DNA hypermethylation and gain of H3K36me3 
across two genomic loci. Bent arrows = TSS; Green bars = CpG islands. See also Figure S4.
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K27ac only (Figure S3H). Genes containing all enhancer 
marks were also determined (termed “All classes”). 
Expression of genes in normal kidney associated with the 
different groups of enhancer marks in a manner consistent 
with their reported functionality; genes marked by K4me1 
alone (“poised” enhancers) demonstrated low expression 
and genes marked with K27ac exhibited higher expression 
(Figure S3I). Genes marked exclusively by H3K4me1 in 
normal adult kidney significantly overlapped with genes 
targeted for hypermethylation in 786-O SETD2 KO 
(pval < 2.089e-07), and were enriched for developmental 
processes (Figure 2F). Finally, we determined the 
differential H3K36me3 status of the normal adult kidney 
enhancer classified genes in our 786-O SETD2 KO cells. 
Genes marked exclusively by H3K4me1 in normal 
adult kidney demonstrated a broad range of differential 
H3K36me3 in 786-O SETD2 KO clones (including 
ectopic gains), while genes marked with H3K27ac in 
normal kidney overwhelming lost H3K36me3 (Figure 
S3J). The mechanism by which poised enhancers are 
targeted for aberrant epigenomic regulation such as gains 
in H3K36me3 and 5mC remains unclear, but enhancers 
linked to genes regulating developmental processes 
are a major target of this effect. This finding is also 
consistent with our RT-PCR data showing up-regulation of 
pluripotency genes and differential effects on germ layer 
markers upon SETD2 inactivation (Figure S1C).
Reconfiguration of 5mC and H3K36me3 by 
SETD2 KO influences gene expression
Since DNA methylation, H3K36me3, and enhancer 
elements all play pivotal roles in gene regulation, we 
next examined the relationship between SETD2 KO-
associated epigenome reconfiguration and changes in gene 
expression. First, we stratified gene expression in parental 
786-O cells into two expression tiers, high and low 
(including genes with no expression), by RPKM values. 
Next, we determined the fold-change in expression for 
both SETD2 KO clones relative to parental cells. Overall, 
most differential expression (≥ 2 fold-change) occurs at 
genes belonging to the low expression tier, with a majority 
of differentially expressed genes being up-regulated upon 
SETD2 inactivation (Figure S4A). Conversely, genes 
within the high expression tier were typically down-
regulated (Figure S4A). The change in H3K36me3 among 
genes stratified by expression tier was then determined. 
H3K36me3 loss induced by SETD2 KO occurred at high 
expressing genes, while low expressing genes tended to 
gain ectopic H3K36me3 (Figure 3A, Figure S4B). Up-
regulated genes from the low expression tier significantly 
overlapped with genes that gained H3K36me3 (pval < 
E-50), while genes that lost H3K36me3 were not enriched 
for differential gene expression (Figure 3B, Figure S4C). 
Integration of DNA methylation level and how it changed 
with SETD2 KO revealed that genes undergoing loss of 
H3K36me3 do not sustain changes in 5mC or expression, 
and that these genes have the typical methylation profile 
of high expressing genes (low promoter 5mC, high 
gene body 5mC, Figure 3C, top). Filtering for genes in 
the high expression tier that lose H3K36me3 revealed 
the extent to which DNA methylation remains the same 
with SETD2 KO (Figure S4D, top). Genes that gain 
H3K36me3, however, show marked changes in both 
5mC and expression, with hypermethylation across all 
regions of the gene and elevated expression (Figure 3C, 
bottom). Indeed, evaluation of overall 5mC at genes 
within the low expression tier that gain H3K36me3 reveals 
hypermethylation in both SETD2 KO clones (Figure S4D). 
Ontology analysis of genes that gain H3K36me3, 5mC, 
and expression demonstrate enrichment for processes 
involved in cell adhesion, signaling, and development 
(Figure S4E). To determine if differential methylation at 
base-pair resolution correlates with changes in H3K36me3 
status and gene expression, we integrated differential 
expression with the categories described previously in 
Figure 2D. Significant overlap of genes changing in 
expression occurred only with hypermethylated CpGs 
in regions of increased H3K36me3 (Figure 3D, Figure 
S4F) indicating that gains, but not losses, of H3K36me3 
specifically influence gene expression upon SETD2 
inactivation. We validated up-regulation of genes that 
gain H3K36me3 and 5mC (Figure 3E) by qRT-PCR 
(Figure S4G). Finally, as epigenetic regulation of 
enhancer elements also influences gene expression, we 
determined if genes linked to a particular combination 
of enhancer marks (as in Figure S3H) were enriched 
for expression changes with SETD2 KO. Indeed, genes 
marked exclusively by H3K4me1 were significantly 
enriched for up-regulation (Figure S4H), the same class 
that displayed enrichment for H3K36me3 gains (Figure 
S3J) and DNA hypermethylation (Figure 2E). Taken 
together, these results indicate that loss of SETD2 function 
induces marked redistribution of H3K36me3 and 5mC that 
positively influences expression of low expressing genes.
dnA hypermethylation induced by setd2 Ko 
occurs over large regions of the genome
Since a large proportion of differential 
hypermethylation occurred at intergenic regions with 
SETD2 inactivation (Figure 2A, Figure S3C), we next 
evaluated whether these were sporadic or coordinated 
events. Low expressing genes adjacent to hypermethylated 
intergenic CpGs were hypermethylated across both 
promoter and gene body regions (Figure 4A). Notably, a 
number of the genes demonstrated elevated H3K36me3 
and expression (Figure 4A). High expressing genes 
adjacent to hypermethylated intergenic CpGs, in contrast, 
did not change their 5mC. Differentially methylated 
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Figure 4: setd2 loss-of-function induces ectopic H3K36me3 and dnA hypermethylation coordinated across large 
regions of the genome. A. Heatmaps demonstrating the average 5mC level, change in 5mC, change in H3K36me3, and overall expression 
change for genes adjacent to hypermethylated (Δβ≥0.2) intergenic CpGs. 5mC level and change in 5mC for CpGs (450K array) in genes 
adjacent to hypermethylated intergenic CpG loci were averaged based on genomic location (P = promoter, B = body, I = intergenic). Each 
row represents a gene. b. Browser shot of a differentially methylated region (DMR) in which DNA hypermethylation, H3K36me3 gains, 
and up-regulation of gene expression occurs. DMR is highlighted in gray. Log2FC = Log2 fold-change in H3K36me3 where red indicates 
gains in H3K36me3 and green indicates loss of H3K36me3. Genes within the DMR are highlighted in red. c. Expression by RNA-seq of 
genes outside (top) and inside (bottom) the DMR. d. Ontology analysis of genes located in DMRs that are conserved between both SETD2 
KO clones. Terms are highlighted by expression change of the genes that contribute. See also Figure S5.
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regions (DMRs) are defined as contiguous regions of 
the genome that undergo conserved changes in DNA 
methylation. Since genes adjacent to hypermethylated 
intergenic CpG sites also display hypermethylation, 
we assayed the SETD2 KO clones for DMRs (defined 
as eight contiguous CpGs with Δβ≥0.2) (Figure S5A). 
Eighty percent of identified DMRs from one SETD2 
KO clone were conserved in the other SETD2 KO clone, 
indicating that these loci are consistently targeted for 
hypermethylation with SETD2 inactivation (Figure S5A). 
DMRs occurred predominately in intergenic regions 
(Figure S5B), coincided with large domains that gained 
H3K36me3 (Figure 4B) (pval < 2.65E-49), and genes 
within the DMR were typically up-regulated as a result 
(Figure 4C). In addition, a significant proportion of genes 
within DMRs are marked by H3K4me1 in normal adult 
kidney (pval < 5.75E-10). Finally, almost all genes within 
DMRs are low expression tier genes, and typically are not 
expressed or are up-regulated by SETD2 KO (Figure S5C). 
Ontology analysis revealed enrichment for biological 
processes involved in development (likely a reflection of 
the genes marked previously by H3K4me1, Figure 2F), 
cell adhesion, and signal transduction (Figure 4D). 
setd2 sirnA knockdown (Kd) induces 
dnA hypermethylation in nccIt embryonic 
carcinoma cells
To determine if DNA hypermethylation is a common 
phenotype induced by SETD2 loss-of-function outside 
the context of an RCC background, we acutely depleted 
SETD2 in NCCIT embryonic carcinoma cells using 
siRNA as we have done previously [31]. Total H3K36me3 
was decreased upon siKD of SETD2 in NCCIT cells 
(Figure S6A) and did not significantly alter expression 
of housekeeping genes, epigenetic modifiers, and PAF 
complex subunits (Figure S6B). Pluripotency genes 
and germ layer markers were differentially expressed 
Figure 5: Acute depletion of SETD2 by siRNA in NCCIT embryonic carcinoma cells recapitulates DNA methylation 
changes observed in setd2 Ko 786-o cells. A. Box plots representing all Δβ-values in the indicated genomic features. b. 
Percentage of differentially methylated CpG sites (ǀΔβǀ ≥ 0.1) classified by methylation change upon SETD2 siKD (hypo/hypermethylation). 
c. Normalized distribution of significantly differentially methylated CpG sites by genomic feature. d. Representative browser shots 
demonstrating conservation of hypermethylation between NCCIT SETD2 siKD and 786-O SETD2 KO. H3K36me3 786-O ChIP-seq tracks 
are provided as a reference for H3K36me3 status across the regions. See also Figure S6.
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with SETD2 siKD (Figure S6B), similar to the changes 
observed in 786-O SETD2 KO cells (Figure S1C). Next 
we assayed genome-wide 5mC patterns with the 450K 
array. Like 786-O SETD2 KO cells, regional analysis 
of 5mC changes revealed hypermethylation occurring 
predominately in intergenic regions (Figure 5A). Analysis 
of the most differentially methylated CpGs (ǀΔβǀ≥0.1) 
showed that > 85% of CpGs became hypermethylated 
upon SETD2 siKD (Figure 5B). Enrichment analysis 
of differentially methylated CpGs demonstrated DNA 
hypomethylation occurring predominately at gene termini, 
while hypermethylation events were enriched in intergenic 
regions (Figure 5C), patterns similar to those observed in 
786-O SETD2 KO cells (Figure S3C). Hypermethylation 
of promoters and gene bodies significantly overlapped 
between SETD2 siKD and SETD2 KO cell models, while 
hypomethylation events overlapped only in gene bodies 
(Figure S6C). Finally, DNA hypermethylation induced 
by SETD2 siKD in NCCIT cells occurred at regions of 
the genome conserved with those observed in 786-O 
SETD2 KO cells (Figure 5D). These were also regions that 
demonstrated ectopic H3K36me3 in the 786-O SETD2 
KO cells (Figure 5D). Taken together, these results show 
that DNA hypermethylation arising from SETD2 loss-
of-function is conserved across cell types and occurs 
with both acute and long-term functional inactivation of 
SETD2.
setd2 mutant primary ccrcc manifests dnA 
hypermethylation consistent with cell line models
After identifying epigenetic patterns conserved 
between different cell lines resulting from depletion of 
SETD2, we next determined if these alterations in 5mC 
occur in primary ccRCCs with SETD2 mutations. Since 
> 90% of ccRCCs have SETD2 LOH, but evidence that 
monoallelic loss of SETD2 impacts global levels of 
H3K36me3 is lacking [13], we identified tumor samples 
from the Cancer Genome Atlas (TCGA) KIRC dataset 
with biallelic inactivation from copy number loss and 
concurrent SETD2 mutation (n = 29) and compared 
these samples to KIRC tumors with no evidence 
of SETD2 mutation or LOH (n = 20). To facilitate 
comparison with our SETD2 KO cell lines, only KIRC 
samples with available 450K array data were used. 
Consistent with genome-wide changes in 5mC observed 
in both of our SETD2 loss-of-function cell line models, 
hypermethylation in the SETD2 mutant primary ccRCCs 
occurred specifically at intergenic regions (Figure 
6A). Focusing on the most differentially methylated 
CpGs (ǀΔβǀ≥0.1) revealed that > 80% of these loci 
sustained hypermethylation (Figure 6B). Enrichment 
profiles for differentially methylated CpGs were also 
consistent with those observed in the cell line models, 
with hypomethylation events enriched at gene termini 
and hypermethylation events enriched at intergenic loci 
(Figure 6C). Indeed, hypermethylated DMRs conserved 
among SETD2 inactivated cell lines and primary tumors 
were identified, illustrating the reproducibility of DNA 
hypermethylation that accompanies loss of SETD2 
function (Figure 6D). The overlap of hypermethylated 
CpGs among all genomic features, and of hypomethylated 
CpGs specifically across gene bodies between SETD2 
mutant cell lines and primary tumors was significant 
(Figure 6E). Ontology analysis of hypermethylated 
genes that overlap among 786-O SETD2 KOs and 
SETD2 mutated ccRCC tumors (Figure S7A) revealed 
enrichment of similar biological process terms, including 
developmental-related, cell adhesion, and transport 
(Figure 6F). A significant proportion of the overlapping 
genes were also marked exclusively by H3K4me1 in adult 
human kidney (pval < 1E-100), indicating that poised 
enhancers are targeted for aberrant epigenetic regulation 
in SETD2 mutant primary tumors.
To determine if changes in H3K36me3 distribution 
were also conserved between our cell line model and 
primary SETD2 mutant ccRCCs, we examined ChIP-
seq data derived from two metastatic primary ccRCCs, 
one harboring WT SETD2 and one with biallelic SETD2 
loss [13]. Locations that lost H3K36me3 under SETD2 
inactivation conditions were highly conserved between 
cell lines and primary tumors (Figure S7B). Ectopic gains 
in H3K36me3, which occur less frequently than losses 
of H3K36me3, were also conserved (Figure S7B), but 
excluded from the SETD2 WT tumor sample. Indeed, loci 
that consistently gain H3K36me3 and 5mC were identified 
among the cell lines and SETD2 mutated primary ccRCC, 
but not the SETD2 WT tumor (Figure S7C). Next, we 
stratified gene expression from the KIRC TCGA normal 
kidney samples into high and low expression tiers, and 
evaluated their 5mC levels. Consistent with the cell lines, 
hypermethylation in SETD2 mutant KIRC ccRCCs was 
focused primarily on genes within the low expression tier, 
and hypomethylation on genes in the high expression tier 
(Figure S7D). Finally, we examined 5mC levels in SETD2 
WT versus mutant ccRCCs stratified by expression tier. 
Although subtle, hypermethylation in the SETD2 mutated 
ccRCCs was observed at genes in the low expression tier, 
while genes in the high expression tier maintained their 
DNA methylation (Figure S7E). Taken together, results 
from the 786-O SETD2 KO cells were highly predictive 
of epigenetic phenotypes that occur as a result of SETD2 
mutation in primary ccRCC. 
setd2 loss-of-function mutations induce dnA 
hypermethylation in other tumor types
As global DNA hypermethylation was consistently 
induced in our models of SETD2 inactivation and in 
primary SETD2 mutant ccRCCs, we next investigated 
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whether inactivating SETD2 mutations in other cancer 
types are associated with a hypermethylation signature. We 
identified samples from the TCGA kidney renal papillary 
cell carcinoma (KIRP) and lung adenocarcinoma (LuCa) 
data collections that harbored SETD2 mutations (two 
tumor types with appreciable numbers of SETD2 mutant 
tumors in TCGA datasets) and analyzed them alongside the 
KIRC dataset [35]. SETD2 mutations were significantly 
associated with global DNA hypermethylation in all three 
tumor types (Figure 7A-7C). Closer examination of 5mC 
Figure 6: epigenetic changes in setd2 inactivation cell line models are recapitulated in SETD2 mutated primary 
ccrccs. A. Box plots representing all Δβ-values in the indicated features in SETD2 mutant ccRCC from the TCGA KIRC dataset. b. 
Percentage of differentially methylated CpG sites (ǀΔβǀ ≥ 0.1) classified by 5mC change in SETD2 mutated relative to WT ccRCC. c. 
Normalized distribution of significantly differentially methylated CpGs by genomic feature. d. Browser shots of regions that demonstrate 
consistent hypermethylation across all SETD2 altered conditions studied. Bottom region is an example of hypermethylation across an 
intergenic region. e. Overlap analysis of differentially methylated CpGs between 786-O SETD2 KO (ǀΔβǀ ≥ 0.2) and SETD2 mutated 
ccRCC (ǀΔβǀ ≥ 0.1) across different genomic features. P = Promoter; B = Gene Body; I = Intergenic. Fisher’s Exact Test was used to 
determine significance. F. Biological process ontology analysis (DAVID) of overlapping hypermethylated genes among 786-O SETD2 KO 
samples and SETD2 mutated ccRCC. See also Figure S7.
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profiles revealed that hypermethylation events in KIRC, 
KIRP, and LuCa were more frequent in number, magnitude 
(change in 5mC), and significance (p-value) in SETD2 
mutant tumors relative to the wild-type counterparts 
(Figure 7D-7F). Unsupervised hierarchical clustering 
of the top 10,000 most variably methylated CpGs from 
the 786-O SETD2 KO samples and the KIRC dataset 
segregated samples based on SETD2 genotype (Figure 
S8A). We next performed unsupervised hierarchical 
clustering based on the 10,000 most variable CpGs 
on the 450K array in each tumor type (Figure 7G-7I), 
revealing two major clusters based on 5mC profiles; one 
cluster dominated by hypermethylation that significantly 
coincided with high prevalence of SETD2 mutation 
(KIRC, p = 1.67E-7; KIRP, p = 0.0048; LuCa, p = 0.025). 
Specifically, 86%, 83%, and 79% of KIRC, KIRP, and 
LuCa, respectively segregated into the expected cluster 
based on SETD2 genotype. It is important to note that 
this analysis included nonsense, missense, and frameshift 
mutations, not all of which may impair SETD2 activity 
Figure 7: SETD2 mutation is associated with a hypermethylation phenotype across multiple tumor types. The average 
methylation value for each SETD2 wild-type (blue) and mutant (red) tumor, as measured by the Infinium 450K for A. ccRCC (KIRC), b. 
papillary renal cell carcinoma (KIRP), and c. lung adenocarcinoma (LuCa). Significance between wild-type and mutant tumors is denoted 
by (*), p < 0.05. d.-F. Volcano plots presenting the number of hypo- and hypermethylated CpGs relative to their significance (-log p-value). 
G.-I. Heatmaps depicting unsupervised hierarchical clustering of the top 10,000 most variable CpGs in ccRCC, pRCC, and LuCa. A color 
bar is shown with low methylation in blue, intermediate in black, and high methylation in yellow. The two major dendrogram clusters are 
colored in red and green. Chi-square testing was used to determine statistical significance between dendrogram clusters. See also Figure S8.
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Figure 8: SETD2 inactivation unveils a hypermethylation signature among tumors induced by dysregulation of 
epigenetic marks and machinery. A. Heatmap of the 200 most conserved hypermethylated CpGs in SETD2 mutant KIRC, KIRP, and 
LuCa. A color bar is shown with low methylation in blue, intermediate in black, and high methylation in yellow. The two major dendrogram 
clusters are colored in red and green (P = 9.42e-6). Tumor stage classification is provided for each primary tumor. Chi-square testing was 
used to determine statistical significance between dendrogram clusters and tumor stages (P = 2.16e-6). b. Ingenuity pathway analysis 
of the genes associated with the top 1,000 most consistently hypermethylated CpGs in SETD2 mutant tumors (-log p-value). c. Model 
for epigenetic regulation of transcription under conditions of SETD2 inactivation. Top panel: Under normal conditions, high expressing 
genes (left) are marked with H3K36me3 and 5mC. Low expressing genes (right), have no H3K36me3 and low to intermediate 5mC across 
the gene body. Intergenic regions also demonstrate intermediate amounts of DNA methylation, and poised enhancers (H3K4me1) lack 
5mC. Bottom panel: Under conditions of SETD2 inactivation, H3K36me3 is lost from high expressing genes (left); however, expression 
remains active and DNMT1 maintains previously established 5mC with the exception of gene termini, as these regions likely maintain 
their methylation status through the recruitment of DNMT3B. Redistribution of H3K36me3 occurs with loss of SETD2 and spreads across 
intergenic regions and low expressing genes. DNMT3B is recruited to nascent H3K36me3 through its PWWP domain and establishes new 
5mC. Low expressing genes transition to a more transcriptionally active state as a result of deregulated epigenetic patterning.
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and/or H3K36me3 status, and this likely contributes to the 
“mis-classification” of some tumors. In addition, there are 
alternative mechanisms by which SETD2 and H3K36me3 
can be deregulated, including loss of 3p21, transcriptional 
regulation, and loss of H3K36me3 substrate (H3K36me1/
me2) due to modulation of H3K36me1/me2 histone 
methyltransferases [36]. 
To better understand the effect of DNA 
hypermethylation resulting from SETD2 inactivation in 
primary tumors, we examined CpGs hypermethylated 
across all three tumor types (KIRC, KIRP, and LuCa) 
to determine if there was a common 5mC signature of 
SETD2 loss (Figure 8A). Independent of tumor type, a 
200 CpG hypermethylation signature was established, 
demonstrating that loss of SETD2 alters the DNA 
methylome. Eighty-eight percent of tumors segregated 
as expected based on SETD2 genotype. SETD2 mutant 
primary tumors derived from KIRC, KIRP, and LuCa 
analyzed in this study were predominantly associated 
with high grade (stages III-IV versus stages I-II (p 
= 2.16e-6)) and higher stage (p = 9.42e-6). We next 
interrogated the top 1,000 most differentially methylated 
CpGs between SETD2 wild-type and mutant tumors using 
Ingenuity Pathway Analysis (IPA) to better understand 
the underlying biological processes that may be affected 
(Figure 8B). The most statistically significant pathway 
enriched was “Transcriptional Regulatory Network in 
Embryonic Stem Cells” including genes such as EOMES, 
MEIS1, and REST. 
To determine if enhancer elements contribute 
disproportionally to the DNA hypermethylation observed 
among the three cancer types investigated, as they 
did in the 786-O cells, we assayed differential 5mC at 
CpGs within regions marked with histone modifications 
linked to different types of enhancers (H3K4me1 only, 
H3K4me1+H3K27ac, H3K27ac only) derived from the 
Epigenome Roadmap datasets (normal adult kidney was 
used for KIRC and KIRP; normal adult lung for LuCa). 
Hypermethylation was consistently enriched among 
all tumor types at regions marked by K4me1 in normal 
tissue but was excluded from K27ac-marked regions 
(Figure S8B). Consistent with our cell line models, 
SETD2 inactivation induced hypermethylation at K4me1 
marked regions across all genomic features (Figure 
S8C) suggesting that enhancers are a common target for 
epigenetic deregulation in SETD2 mutant tumors.
dIscussIon
In this study, we used cell culture models and 
primary tumors to examine how SETD2 loss-of function 
mutations drive tumorigenesis. Isogenic 786-O SETD2 
deficient ccRCC cells demonstrated marked redistribution 
of H3K36me3. While loss of H3K36me3 in gene bodies 
predominated, substantial ectopic H3K36me3, focused 
largely on intergenic regions, was also observed. 
Inactivation of SETD2 resulted in marked effects on 
the DNA methylome dominated by genome-wide 
hypermethylation. DNA hypermethylation significantly 
co-occurred at sites of ectopic H3K36me3 indicating 
that this mark profoundly influences 5mC placement. 
Other regions of the genome without appreciable ectopic 
H3K36me3 were also subject to DNA hypermethylation, 
suggesting widespread disruption of 5mC targeting, 
perhaps due to loss of DNMT3 containment in 
H3K36me3-rich domains. Redistribution of H3K36 
and 5mC resulted in up-regulation of previously non-/
low-expressed genes enriched for the poised enhancer 
mark H3K4me1 in normal adult kidney. Acute depletion 
of SETD2 in an unrelated VHL competent cell line led 
to a similar effect on 5mC distribution showing that the 
impact of SETD2 loss-of-function is independent of cell 
type and method of SETD2 inactivation. Changes in 5mC 
were conserved in primary ccRCC with biallelic SETD2 
inactivation, in SETD2-mutant papillary RCC (a distinct 
tumor of the kidney), and in lung adenocarcinomas with 
SETD2 mutations, and resulted in a distinct 5mC signature 
that efficiently clustered tumors by SETD2 genotype and 
higher tumor grade and stage, consistent with findings 
by us [2, 13] and others [37-39] that SETD2 mutations 
are generally linked to poor prognosis and/or metastasis. 
Taken together, our results show that SETD2 mutant 
tumors represent a new DNA hypermethylator class 
and that genome-wide redistribution of 5mC caused by 
SETD2 inactivation, particularly at enhancers, represents 
one mechanism by which this mutation may promote de-
differentiation and cancer progression.
 While inactivation of SETD2 in 786-O cells 
resulted in large-scale losses of H3K36me3, particularly 
across bodies of high expressing genes that represent the 
major sink for H3K36me3 in the genome, we unexpectedly 
also observed ectopic gains in H3K36me3 across low 
expressed genes and intergenic regions. This finding is 
consistent, however, with our previous H3K36me3 ChIP-
seq analysis of SETD2 mutant primary ccRCC where we 
observed ectopic H3K36me3 in a SETD2 mutant tumor 
at a region that influenced an RNA splicing event [13]. 
In the primary tumor analysis it was difficult to rule out 
intratumoral heterogeneity or normal cell contamination 
as a cause for ectopic H3K36me3, however our 786-O 
isogenic model consistently shows overlapping ectopic 
H3K36me3 peaks with SETD2 mutant primary ccRCC, 
underscoring the validity of this finding. SETD2 is thought 
to be the sole H3K36 trimethylase in mammals [11, 12], 
although this is largely based on lower sensitivity global 
quantification methods such as immunohistochemistry or 
total H3 western blotting. Although we cannot completely 
rule out the possibility of some residual activity from the 
SETD2 locus in our 786-O cells, we believe the most 
likely mediator of the ectopic H3K36me3 is another 
histone methyltransferase that methylates the H3K36 
position, but does not typically perform trimethylation. 
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H3K36me1/me2 are regulated by a diverse group of 
proteins, including: NSD1 (KMT3B), NSD2 (MMSET/
WHSC1), NSD3 (WHSC1L), SETD3, ASHL1, SETMAR 
(METNASE), and SMYD2. Use of varied substrates, 
assay conditions, and cell types have likely led to 
inconsistencies in the reported substrate preferences of 
each enzyme [40]. The NSD family members, for example, 
preferentially mono- and dimethylate K36 in vivo [40], but 
are capable of trimethylating K36 in vitro [36]. Although 
we did not observe significant changes in expression of 
NSD family members in our SETD2 KO clones (based 
on RNA-seq, data not shown), it appears plausible one of 
them could adopt this activity in the absence of normal 
SETD2 activity and our isogenic 786-O cells represent 
a good model for identifying this activity. Given that 
the SETD2 inactivation-induced ectopic H3K36me3 is 
linked to genome-wide DNA hypermethylation and gene 
expression changes associated with dedifferentiation, this 
activity could represent a novel drug target in SETD2 
mutant tumors.
Prior studies examining the relationship between 
DNA and H3K36 methylation focused on the impact of 
H3K36me3 loss to methylated regions of the genome. 
Hahn et al. hypothesized that 5mC and H3K36me3 were 
established independently since SETD2 depletion did 
not change 5mC at gene bodies that lost H3K36me3, 
and conversely H3K36me3 distribution did not change 
in HCT116 cells depleted of DNMT1 and DNMT3B 
[41]. Our results showing that highly expressed genes in 
786-O SETD2 KO clones that lost H3K36me3 generally 
maintained their 5mC supports these observations. The 
TCGA consortium reported ccRCC DNA hypomethylation 
was enriched at sites marked by H3K36me3 in normal 
kidney [3], which is consistent with our findings that 5mC 
was lost predominantly at H3K36me3-high gene termini. 
In addition, the TCGA reported DNA hypermethylation 
focused at CpGs not previously marked by H3K36me3 in 
normal adult kidney [3]. This also is consistent with our 
results in that many regions gaining 5mC under SETD2 
loss conditions are not marked by H3K36me3, rather it 
is these loci that gain both ectopic H3K36me3 and 5mC. 
Finally, our findings are consistent with those of Sato et 
al. who stratified differential 5mC in ccRCCs into three 
tiers (low, intermediate, and high) and observed that 92% 
of SETD2 mutant tumors were present in the intermediate 
and high 5mC tiers [42]. Thus collectively our findings, 
supported by the TCGA KIRC dataset, firmly link SETD2 
loss-of-function to a global DNA hypermethylation 
phenotype and more aggressive disease.
Previous work from our laboratory and others 
showed that DNMT3B was particularly enriched at 
actively transcribed H3K36me3-marked gene bodies 
[21, 30, 31], and that H3K36me3 recognition by the 
DNMT3B PWWP domain is important for its ability to 
methylate these regions [25, 26]. Based on these studies 
and our results, we hypothesize that global genome 
DNA hypermethylation under SETD2 loss-of-function 
conditions results from two mechanisms (Figure 8C), (i) 
recruitment of DNMT3B to ectopic H3K36me3 regions 
followed by de novo methylation, and (ii) loss of normal 
DNMT3B tethering to gene bodies, allowing it to gain 
access to normally unmethylated regions of the genome 
(loss of ‘containment’). We cannot rule out the possible 
involvement of other DNMTs in this process. In regions 
already methylated, SETD2 inactivation does not result 
in 5mC loss because methylation is already established 
and thus is maintained by DNMT1. The exception to this 
appears to be gene termini, where loss of H3K36me3 is 
linked to 5mC loss. Interestingly, ChIP-seq demonstrated 
DNMT3B was most enriched at gene termini [30], 
indicating that it might be responsible for both 
establishment and maintenance of 5mC at gene 3’-ends 
(Figure 8C). It is therefore of interest to examine whether 
5mC regulates aspects of 3’-end processing. Poised 
normal tissue enhancers were also a prominent target of 
SETD2 inactivation-induced ectopic H3K36me3 and 
DNA hypermethylation. Interestingly, active enhancers in 
human cells are enriched for H3K36me3 [43], consistent 
with the up-regulation of genes associated with these 
sequences we observe. The presence of unproductive non-
coding RNA transcripts emanating from active enhancers 
[44] is consistent with acquisition of both H3K36me3 
and 5mC, since both marks are recruited to actively 
transcribed loci. Thus the presence of 5mC at or flanking 
certain enhancers may be indicative of enhancer activation 
much in the same way gene body 5mC is linked positively 
to gene activity [21].
SETD2 mutation or down-regulation occurs across 
a broad spectrum of tumor types [3, 35, 38] although in 
many of these its frequency is relatively low ( < 10%) 
making detailed analysis of its effects feasible only with 
large datasets. To begin to assess whether the impact of 
SETD2 mutations on 5mC localization was conserved 
in other tumor types, we expanded our analysis to 
two large public datasets, papillary RCC and lung 
adenocarcinoma [35]. In both a distinct type of kidney 
cancer not characterized by chromosome 3p LOH or VHL 
inactivation, and a tumor of completely different cellular 
origin, we observed a DNA hypermethylation phenotype 
strongly linked to SETD2 mutation. SETD2 mutations are 
independently acquired within multiple parts of the same 
papillary RCC [37], suggesting strong selective pressure 
to inactivate the K36me3 pathway, and SETD2 mutations 
are enriched in relapsed B-ALL [39], reinforcing the link 
between this mutation and tumor progression. Our results 
support this notion as a majority of the SETD2 mutated 
hypermethylated tumors were associated with more 
aggressive stage and grade. CIMP (CpG island methylator 
phenotype) is now recognized in many different tumor 
types and in the case of glioma is caused by mutations in 
IDH1/IDH2. IDH mutations operate in part by inhibiting 
TET-mediated DNA demethylation, but also render 
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the tumors more sensitive to DNA hypomethylating 
agents [45, 46]. Preclincial studies have shown that the 
DNA methylation inhibitor 5-aza-2’-deoxycytidine 
(5-azadC) effectively reverses DNA hypermethylation 
observed in IDH1 mutant gliomas, induces tumor stem 
cell differentiation, and inhibits tumor growth in mouse 
models [46]. Our identification of SETD2 as a novel 
driver of a DNA hypermethylation phenotype suggests 
that such tumors might also be more susceptible to DNA 
hypomethylating agents like 5-azadC. Therefore while 
many chromatin regulator gene mutations are not currently 
targetable with specific therapies, the interplay between 
marks, exemplified by 5mC and H3K36me3 described 
here or IDH1 and 5mC in glioma, suggests that multiple 
epigenetic regulator mutations may converge on and 
deregulate 5mC patterns as a common method to promote 
tumorigenesis. As such, DNA demethylating agents may 
be more generally applicable as a therapy to target tumors 
with epigenetic regulator mutations. Our results identify 
a highly conserved DNA hypermethylation phenotype 
induced by SETD2 inactivation that functionally 
modulates the gene expression program of renal cell 
cancers, suggesting that DNA demethylating agents 
represent a potential rational therapy to target SETD2 loss 
of function tumors.
MAterIAls And MetHods
cell culture, setd2 depletion, dnA/rnA 
extraction, and quantification of 5mC content by 
mass spectrometry
786-O parental and SETD2 KO derivatives were 
grown in RPMI1640 medium supplemented with 
10% heat-inactivated fetal bovine serum and 2 mM 
L-glutamine. Briefly, SETD2 was targeted by zinc finger 
nucleases for deletion and two isogenic clones with 
frameshifts were generated [13]. SETD2 KO1 contains 
a 4 base pair deletion and KO2 contains an 11 base pair 
deletion confirmed by Sanger sequencing [13]. 786-O 
parental and SETD2 KO derivatives were validated by 
cell line authentication provided by ATCC (data available 
upon request). NCCIT cells were grown in McCoy’s 
5A medium supplemented with 10% heat-inactivated 
fetal bovine serum and 2 mM L-glutamine. The On-
TARGETplus siRNA SMARTpool (Dharmacon, Thermo 
Scientific) targeting a single gene was used against SETD2 
(L-012448-00-0005). Transfection with a negative control 
non-targeting siRNA (D-001206-13-20; Dharmacon, 
Thermo Scientific) was performed in parallel. SiRNA 
transfection was performed with PepMute transfection 
reagent (SignaGen) according to the manufacturer 
protocol as previously described [31]. Total RNA was 
extracted by Trizol homogenization and purified according 
to the manufacturer’s protocol (Life Technologies). 
Genomic DNA was extracted by proteinase K digestion 
and phenol:chloroform extraction. A portion of this 
genomic DNA was also used to quantify total genomic 
5mC levels by LC-MS/MS exactly as described [32]. 
Samples for MS were run in duplicate at the Biomarker 
Mass Spectrometry Facility at the University of North 
Carolina, Environmental Sciences & Engineering Gillings 
School of Global Public Health.
expression analysis by rnA-seq and qrt-Pcr
RNA-seq data was downloaded from the Gene 
Expression Omnibus (GEO) and aligned to genome build 
h19 using TopHat v2 [47]. A value of 0.01 was added 
to all gene RPKM values to account for genes with no 
expression and prevent artificially large fold-changes in 
expression [48]. A cutoff of ≥ 2-fold-change in expression 
was considered differential expression [48]. cDNA 
synthesis and qRT-PCR was performed in triplicate as 
described [30]. Primer sequences for ChIP, MeDIP, 
and qRT-PCR are listed in Table S1 in Supplemental 
Information.
Histone extraction and western blotting
Adherent cells were scraped and washed with PBS. 
Ice-cold lysis buffer (20 mM Tris, 137 mM NaCl, 1.5 mM 
MgCl2, 1mM EDTA, 10% Glycerol, 1% Triton X-100) 
with protease inhibitors was added to the cell pellet (900 
µl/100 mm dish). The lysis reaction was sonicated on ice 
at 40W for 30 seconds at 50% duty (Branson 450 Sonifier) 
and centrifuged at 13,200 RPM for 20 minutes at 4ºC. 
The supernatant was collected and assayed for protein 
concentration using BCA. Protein extracts (2 µg) were 
size-separated on an 18% acrylamide gel and transferred 
to PVDF membrane. Membranes were blocked for one 
hour at room temperature using 5% BSA/0.1% TBST (50 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20). 
Membranes were then incubated with the primary antibody 
for 1.5 hours at room temperature and rinsed four times in 
0.1% TBST. Membranes were incubated in appropriate 
secondary antibody diluted 1:20,000 in 5% BSA/0.1% 
TBST for one hour at room temperature and rinsed. Pierce 
Pico was added for five minutes at room temperature for 
detection. Antibodies and dilutions used are: histone H3 
(Abcam 1791 1:1000), H3K36me1 (Abcam 9048 1:1000), 
H3K36me2 (Abcam 9049 1:1000), H3K36me3 (Abcam 
9050 1:1000). Dot blotting was performed following the 
Abcam protocol.
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MedIP pull-down assays
MeDIP experiments were performed as previously 
described [31] with the 33D3 5mC antibody (Diagenode). 
chIP-qPcr
ChIP-pull downs for H3K36me3 (Active Motif 
61021) were performed using an in-house protocol as 
previously described [13] and detailed in Supplemental 
Information.
chIP-seq data analysis
ChIP-seq data processing was conducted as 
previously described [30] and detailed in Supplemental 
Information.
450K array data analysis
DNA samples were processed on the 
HumanMethylation450 BeadChip array (Illumina) and 
analyzed as previously described [31, 49] and detailed in 
the Supplemental Information. 
Gene ontology and pathway analysis
Ontology analysis was performed using GO_BP 
within the DAVID bioinformatics database with Benjamini 
correction for multiple testing [50] or Ingenuity Pathway 
Analysis (Qiagen) using standard program parameters.
Significance testing
The Fisher Exact test with a two-tailed p-value 
calculation was used for testing the significance of data 
set comparisons as described previously for similar data 
sets [51]. For added stringency, a modified EASE score 
was applied to all Fisher Exact tests. Chi-square testing 
was used to determine significance of clustering and tumor 
grade. 
tcGA sample Ids
Gene expression, exome sequencing, 450K array, 
and tumor grade data was generated by the Cancer 
Genome Atlas and downloaded from http://cancergenome.
nih.gov/. Patient sample identification numbers used for 
KIRC, KIRP, and LuCa 450K array analysis are provided 
in Tables S2, S3, and S4, respectively in Supplemental 
Information. Data was downloaded from TCGA on 
4/23/2015.
Availability of supporting data
450K array data for 786-O parental, SETD2 KO1 
and KO2, and siKD of SETD2 in NCCIT cells have been 
deposited in GEO (GSE70645). NCCIT no-target control 
(NTC) was previously deposited to GEO under accession 
GSE54840 (sample GSM1527531). 
Previously released dataset accession numbers are 
provided in Table S5 in Supplemental Information. 
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